 CymaBay Therapeutics Inc NASDAQ: CBAY has received 100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis PBC. Under the terms of the transaction, CymaBay will receive up to 100 million of seladelpar development costs, of which 75 million will be received in three installments over approximately six months. 